GVK BIO Enters into Research Collaboration with Endo Pharmaceuticals

Hyderabad-based drug discovery research and development CRO GVK Biosciences today said that it has entered into a collaboration agreement with US-based Endo Pharmaceuticals, which focused on discovering novel small molecules targeting an exciting protein.

Under this agreement GVK BIO will use its discovery expertise to deliver a clinical candidate and Endo will develop and commercialise the product arising out of this collaboration. This collaboration arose out of a newly-launched concept at GVK BIO named early discovery assets (EDAT).

"This collaboration confirms the value of our differentiated EDATMconcept, conceived to collaborate with pharmaceutical partners on discovery projects, from target to clinical candidates," said Manni Kantipudi, CEO of GVK BIO in a statement.

GVK Biosciences, through its internal expertise in computational chemistry, discovery biology and medicinal chemistry, is building a portfolio of discovery project assets for potential early stage partnering. This early stage asset portfolio is focused around pain and inflammation. GVK Biosciences develops these assets to a stage of demonstrated value and then looks to partner and co-develop them with life science company.